Johnson & Johnson researches and develops, manufactures, and sells various products in the health-care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Some of its well-known brands include Tylenol-fever, Listerine-bad breath, Splenda-no-calorie sweetener, Neutrogena-skin care, Pepcid-heartburn, Zyrtec - allergy, Motrin-ibuprofen, Sudafed-allergy, and plenty more. The company was founded in 1885 and is based in New Brunswick, New Jersey.
JNJ Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Johnson & Johnson. To summarize, we found that Johnson & Johnson ranked in the 31th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Johnson & Johnson, consider:
The company has produced more trailing twelve month cash flow than 97.59% of its sector Healthcare.
The business' balance sheet reveals debt to be 8% of the company's capital (with equity being the remaining amount). Approximately just 22.84% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
JNJ's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 37.74% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Johnson & Johnson? See BAX, ICLR, BIO, HOLX, and LNTH.
The rollout of the coronavirus vaccine continues to be a bit bumpy in the US, bogged down by everything from states having complex recipient tiers to follow, to supply limits. President-elect Joe Biden delivered remarks on Friday that laid out his plan to significantly improve the COVID vaccine rollout after next week, when he and Vice President-elect Kamala Harris take office. Meanwhile, interim findings associated with Johnson & Johnson's coronavirus vaccine trial show significant promise, suggesting that yet another COVID vaccine will receive authorization in the US soon. News surrounding the coronavirus vaccine continues to mount, with the end of the week bringing a number of new developments -- including the Trump administration misleading the nation about the size of the US vaccin...
ReportsnReports.com the exclusive leading provider of market research reports published research report on “Global Knee Implants Market Research Report 2020”. The Global Knee Implants Market Report is a professional and in-depth study on the current state of the Knee Implants Market. The
The drug in clinical trials has shown up to 100% efficacy with side effects comparable to other vaccines. The anti-coronavirus vaccine candidate Ad26.COV2.S from Johnson & Johnson (developed by its subsidiary, Janssen) has successfully completed phase I / IIa clinical trials. The research results are published in the New England Journal of Medicine. It is noted […] For more stories like Johnson & Johnson reveals the results of the COVID vaccine trials , please click here Revyuh .
COVID-19 Outbreak-Global Pharma and OTC Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support.